389 related articles for article (PubMed ID: 16859903)
1. Effects of cyclooxygenase inhibition on the gastrointestinal tract.
Radi ZA; Khan NK
Exp Toxicol Pathol; 2006 Nov; 58(2-3):163-73. PubMed ID: 16859903
[TBL] [Abstract][Full Text] [Related]
2. COX-2-selective inhibitors (COXIBs): gastrointestinal safety.
Pronai L; Hritz I; Molnar B; Herszenyi L; Tulassay Z
Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):23-30. PubMed ID: 14552701
[TBL] [Abstract][Full Text] [Related]
3. Pathophysiology of cyclooxygenase inhibition in animal models.
Radi ZA
Toxicol Pathol; 2009 Jan; 37(1):34-46. PubMed ID: 19234234
[TBL] [Abstract][Full Text] [Related]
4. [Mechanism of inhibition OF COX-2 and COX-3 in gastrointestinal damage induced by NSAID in rats ].
Laudanno OM; San Miguel P; Aramberry LJ; Cesolari JA
Acta Gastroenterol Latinoam; 2003; 33(4):183-5. PubMed ID: 14708469
[TBL] [Abstract][Full Text] [Related]
5. Dose-dependent immunomodulatory effects of acetylsalicylic acid and indomethacin in human whole blood: potential role of cyclooxygenase-2 inhibition.
Härtel C; von Puttkamer J; Gallner F; Strunk T; Schultz C
Scand J Immunol; 2004 Oct; 60(4):412-20. PubMed ID: 15379866
[TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: selective COX-2 inhibitors and beyond.
Coruzzi G; Venturi N; Spaggiari S
Acta Biomed; 2007 Aug; 78(2):96-110. PubMed ID: 17933277
[TBL] [Abstract][Full Text] [Related]
7. Nonsteroidal anti-Inflammatory drugs and cardiovascular risk.
Howard PA; Delafontaine P
J Am Coll Cardiol; 2004 Feb; 43(4):519-25. PubMed ID: 14975457
[TBL] [Abstract][Full Text] [Related]
8. Pathophysiology of cyclooxygenases in cardiovascular homeostasis.
Sellers RS; Radi ZA; Khan NK
Vet Pathol; 2010 Jul; 47(4):601-13. PubMed ID: 20418470
[TBL] [Abstract][Full Text] [Related]
9. Genetic tools to tailor cancer prevention by NSAIDs.
Ulrich CM; Bigler J; Potter JD
Discov Med; 2006 Apr; 6(32):71-4. PubMed ID: 17234129
[TBL] [Abstract][Full Text] [Related]
10. Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray?
Hersh EV; Lally ET; Moore PA
Curr Med Res Opin; 2005 Aug; 21(8):1217-26. PubMed ID: 16083531
[TBL] [Abstract][Full Text] [Related]
11. [Is there a future for COX-2 inhibitors?].
Yodfat Y
Harefuah; 2004 Nov; 143(11):820-4, 837. PubMed ID: 15603272
[TBL] [Abstract][Full Text] [Related]
12. NSAIDs, coxibs, CINOD and H2S-releasing NSAIDs: what lies beyond the horizon.
Fiorucci S; Santucci L; Distrutti E
Dig Liver Dis; 2007 Dec; 39(12):1043-51. PubMed ID: 17997373
[TBL] [Abstract][Full Text] [Related]
13. Prostaglandins and inflammation: the cyclooxygenase controversy.
Morteau O
Arch Immunol Ther Exp (Warsz); 2000; 48(6):473-80. PubMed ID: 11197601
[TBL] [Abstract][Full Text] [Related]
14. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Rahme E; Nedjar H
Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
[TBL] [Abstract][Full Text] [Related]
15. Safety of anti-inflammatory treatment--new ways of thinking.
Brune K
Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i16-20. PubMed ID: 14752171
[TBL] [Abstract][Full Text] [Related]
16. An update on eicosanoids and inhibitors of cyclooxygenase enzyme systems.
Sharma S; Sharma SC
Indian J Exp Biol; 1997 Oct; 35(10):1025-31. PubMed ID: 9475035
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase and nitric oxide systems in the gut as therapeutic targets for safer anti-inflammatory drugs.
Whittle BJ
Curr Opin Pharmacol; 2004 Dec; 4(6):538-45. PubMed ID: 15525540
[TBL] [Abstract][Full Text] [Related]
18. Clinical perspectives of anti-inflammatory therapy in the elderly: the lipoxigenase (LOX)/cycloxigenase (COX) inhibition concept.
Gaddi A; Cicero AF; Pedro EJ
Arch Gerontol Geriatr; 2004; 38(3):201-12. PubMed ID: 15066307
[TBL] [Abstract][Full Text] [Related]
19. Effects of cyclooxygenase inhibition on bone, tendon, and ligament healing.
Radi ZA; Khan NK
Inflamm Res; 2005 Sep; 54(9):358-66. PubMed ID: 16273333
[TBL] [Abstract][Full Text] [Related]
20. Choosing nonselective NSAIDs and selective COX-2 inhibitors in the elderly. A clinical use pathway.
Stillman MJ; Stillman MT
Geriatrics; 2007 Feb; 62(2):26-34. PubMed ID: 17291140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
